Isotype	O
-	O
specific	O
inhibitors	O
of	O
the	O
glycolytic	O
key	O
regulator	O
pyruvate	O
kinase	O
subtype	O
M2	O
moderately	O
decelerate	O
tumor	B-Cell
cell	I-Cell
proliferation	O
.	O

Tumor	B-Cell
cells	I-Cell
express	O
the	O
glycolytic	O
regulator	O
pyruvate	O
kinase	O
subtype	O
M2	O
(	O
M2	O
-	O
PK	O
)	O
,	O
which	O
can	O
occur	O
in	O
a	O
tetrameric	O
form	O
with	O
high	O
affinity	O
to	O
its	O
substrate	O
phosphoenolpyruvate	O
(	O
PEP	O
)	O
and	O
a	O
dimeric	O
form	O
with	O
a	O
low	O
PEP	O
affinity	O
.	O

The	O
transition	O
between	O
both	O
conformations	O
contributes	O
to	O
the	O
control	O
of	O
glycolysis	O
and	O
is	O
important	O
for	O
tumor	B-Cell
cell	I-Cell
proliferation	O
and	O
survival	O
.	O

Here	O
we	O
targeted	O
M2	O
-	O
PK	O
by	O
synthetic	O
peptide	O
aptamers	O
,	O
which	O
specifically	O
bind	O
to	O
M2	O
-	O
PK	O
and	O
shift	O
the	O
isoenzyme	O
into	O
its	O
low	O
affinity	O
dimeric	O
conformation	O
.	O

The	O
aptamer	O
-	O
induced	O
dimerization	O
and	O
inactivation	O
of	O
M2	O
-	O
PK	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
the	O
PK	O
mass	O
-	O
action	O
ratio	O
as	O
well	O
as	O
ATP	O
:	O
ADP	O
ratio	O
in	O
the	O
target	O
cells	B-Cell
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
M2	O
-	O
PK	O
-	O
binding	O
peptide	O
aptamers	O
moderately	O
reduced	O
the	O
growth	O
of	O
immortalized	O
NIH3T3	B-Cell
cell	I-Cell
populations	I-Cell
by	O
decelerating	O
cell	B-Cell
proliferation	O
,	O
but	O
without	O
affecting	O
apoptotic	O
cell	B-Cell
death	O
.	O

Moreover	O
,	O
the	O
M2	O
-	O
PK	O
-	O
binding	O
peptide	O
aptamers	O
also	O
reduced	O
the	O
proliferation	O
rate	O
of	O
human	O
U	B-Cell
-	I-Cell
2	I-Cell
OS	I-Cell
osteosarcoma	I-Cell
cells	I-Cell
.	O

In	O
the	O
present	O
study	O
,	O
we	O
developed	O
the	O
first	O
specific	O
inhibitors	O
of	O
the	O
pyruvate	O
kinase	O
isoenzyme	O
type	O
M2	O
and	O
present	O
evidence	O
that	O
these	O
inhibitors	O
moderately	O
decelerate	O
tumor	B-Cell
cell	I-Cell
proliferation	O
.	O

